Cypralis and Gilead Sciences have agreed that Cypralis will have exclusive development and commercialization rights to certain macrocyclic inhibitors of peptide bond isomerases, in all fields except for oncology and virology. This follows a multi-year drug discovery collaboration between Selcia Ltd. and Gilead under which Selcia provided integrated drug discovery services to support Gilead’s liver disease research programs. The research phase ended in 2013 and Selcia’s rights have since been tra...